Abstract #3431

Anti-FGFR1/KLB treatment reduces hepatic fat fraction in a murine model of NAFLD

Maj Hedehus¹, Mark Z. Chen², Jose Zavala-Solorio², Lance Kates², Oded Foreman³, Junichiro Sonoda², and Richard A. D. Carano¹

¹Biomedical Imaging, Genentech, Inc., South San Francisco, CA, United States, ²Molecular Biology, Genentech, Inc., South San Francisco, CA, United States, ³Research Pathology, Genentech, Inc., South San Francisco, CA, United States

Anti-FGFR1/KLB is a novel experimental therapy to treat metabolic disorders and reverse lipid accumulation in the liver. MRI estimates of proton density fat fraction demonstrated a dose-dependent anti-FGFR1/KLB treatment effect in a murine model of NAFLD.

This abstract and the presentation materials are available to members only; a login is required.

Join Here